Hatley Health Care Inc | |
300 Medical Center Drive, Clanton, Alabama 35045 | |
(205) 755-4960 | |
Name | Hatley Health Care Inc |
---|---|
Location | 300 Medical Center Drive, Clanton, Alabama |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 201 |
Occupancy Rate | 48.66% |
Medicare ID (CCN) | 015023 |
Legal Business Name | Hatley Health Care, Inc. |
Ownership Type | For Profit - Corporation |
NPI Number | 1780779439 |
Organization Name | HATLEY HEALTH CARE, INC. |
Address | 300 Medical Center Dr, Clanton, AL 35045 |
Phone Number | 205-755-4960 |
News Archive
A clinical trial evaluates - in humans - a drug, device or mode of therapy for a disease. All therapies put into use in the U.S. go through a rigorous process of testing, culminating in evaluation of the treatment in human research participants. In order to test new treatments, clinical trial investigators at research institutions like UK must recruit participants willing to contribute to science, while often reaping the benefits of advanced treatment for themselves, and gaining access to top clinicians and the latest medical information.
The results of all clinical trials for new drugs and procedures must be released publicly if people are to get the full facts about their medical treatment, says a letter in this week's BMJ.
Researchers at the University of California, Riverside have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. The research could lead to new therapies for preventing cancer metastasis.
To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.
› Verified 4 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
A clinical trial evaluates - in humans - a drug, device or mode of therapy for a disease. All therapies put into use in the U.S. go through a rigorous process of testing, culminating in evaluation of the treatment in human research participants. In order to test new treatments, clinical trial investigators at research institutions like UK must recruit participants willing to contribute to science, while often reaping the benefits of advanced treatment for themselves, and gaining access to top clinicians and the latest medical information.
The results of all clinical trials for new drugs and procedures must be released publicly if people are to get the full facts about their medical treatment, says a letter in this week's BMJ.
Researchers at the University of California, Riverside have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. The research could lead to new therapies for preventing cancer metastasis.
To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.
› Verified 4 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 10.24 | 14.46 |
Percentage of long-stay residents who lose too much weight | 5.62 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 87.16 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.87 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 4.65 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 2.15 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0.44 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 30.54 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 88.14 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 15.3 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.94 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 10.3 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.23 | 95.98 |
Percentage of short-stay residents who made improvements in function | 0 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.34 | 82.93 |
News Archive
A clinical trial evaluates - in humans - a drug, device or mode of therapy for a disease. All therapies put into use in the U.S. go through a rigorous process of testing, culminating in evaluation of the treatment in human research participants. In order to test new treatments, clinical trial investigators at research institutions like UK must recruit participants willing to contribute to science, while often reaping the benefits of advanced treatment for themselves, and gaining access to top clinicians and the latest medical information.
The results of all clinical trials for new drugs and procedures must be released publicly if people are to get the full facts about their medical treatment, says a letter in this week's BMJ.
Researchers at the University of California, Riverside have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. The research could lead to new therapies for preventing cancer metastasis.
To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.
› Verified 4 days ago
Hatley Health Care Inc Location: 300 Medical Center Drive, Clanton, Alabama 35045 Phone: (205) 755-4960 |